



## *In this issue:*

**2** [Cold weather injuries among the active and reserve components of the U.S. Armed Forces, July 2018–June 2023](#)

**12** [Clinically diagnosed sunburn among active component service members, U.S. Armed Forces, 2014–2022](#)

*Lynn A. Van Airsdale, DO, MPH; Shauna Stahlman, PhD, MPH; Kayli Hiban, MPH; Natalie Y. Wells, MD, MPH*

**15** [Surveillance snapshot: Influenza immunization among U.S. Armed Forces health care workers, August 2018–April 2023](#)

**16** [Commentary: The role of vaccines in combatting the potential “tripledemic” of influenza, COVID-19 and RSV](#)

*John K. Iskander, MD, MPH; Katie M. Martinez, PharmD; Nicole Hsu, MD, MPH*

**19** [Reportable medical events at Military Health System facilities through week 39, ending September 30, 2023](#)

*Matthew W. R. Allman, MPH; Anthony R. Marquez, MPH; Katherine S. Kotas, MPH*

## Cold Weather Injuries Among the Active and Reserve Components of the U.S. Armed Forces, July 2018–June 2023

From July 2022 through June 2023, a total of 423 members of the active (n=376) and reserve (n=47) components of the U.S. Armed Forces had at least 1 cold weather injury. The crude overall incidence rate of cold injury among all active component service members (ACSM) during the 2022-2023 cold season was 28.5 per 100,000 person-years (p-yrs), 15.2% lower than the rate observed during the 2021-2022 cold season (33.6 per 100,000 p-yrs). The rates of cold injuries varied among the Armed Forces, with the highest rates per 100,000 p-yrs observed in the Army, at 50.9, followed by the Marine Corps, at 32.2, the Air Force, at 18.9, the Navy, at 8.1, and the Coast Guard at 5.1. Consistent with previous cold seasons, frostbite (54.0%) remained the most common type of cold injury among ACSM during the 2022-2023 cold season, while the proportions of hypothermia and immersion injuries were 16.5% and 30.3%, respectively. Cold injury rates among ACSM during the 2018 to 2023 cold seasons were generally highest for males, non-Hispanic Blacks, those under 20 years of age, and enlisted members. The number of cold injuries identified in service members deployed outside the U.S. during the 2022-2023 cold season (n=10) was comparable to the 2 preceding cold seasons (11 in 2020-2021 and 12 in 2021-2022), with frostbite accounting for half (n=5) of the 2022-2023 cases.

Cold injuries are of significant military concern because of their adverse impact on operations and the high financial costs of treatment and disability.<sup>1,2</sup> In response, the U.S. Armed Forces have developed and are continually improving their training, doctrine, procedures, and protective equipment and clothing to counter the threat of cold environments.<sup>3-8</sup> Although these measures are highly effective, cold injuries continue to affect hundreds of service members each year due to exposure to both cold and wet environments.<sup>9</sup>

Military training or mission requirements in cold and wet weather conditions can preclude immediate warm or dry shelter, the ability to change wet or damp clothing, or even healthy physical activity.<sup>2-4</sup>

Continuous surveillance of cold weather injuries is essential to inform measures for reducing their impacts and remind leaders of this predictable threat. The Department of Defense guidelines for reportable medical events (RMEs) require reporting of cases of hypothermia, freezing peripheral injuries (e.g., frostbite), and non-freezing peripheral injuries (e.g., immersion injuries, chilblains).<sup>10</sup>

Cold injuries can be broadly categorized in 2 major groups: those with a central effect, and those primarily affecting peripheral parts of the body. Hypothermia is a classic example of a central cold injury, which occurs when the body's core temperature falls below 95°F.<sup>7</sup> Freezing atmospheric temperatures are not required to produce hypothermia.<sup>11</sup> Severe hypothermia can

### What are the new findings?

For all ACSM, the rate of cold weather injuries in 2022-2023 decreased by 15.2% compared to the preceding cold season. The decrease was most pronounced in the Marine Corps, with a 22.0% reduction in the incidence rate of cold injuries. This year's report includes cold injury rates for the Coast Guard.

### What is the impact on readiness and force health protection?

Cold injuries are a predictable and preventable threat. Continuous surveillance is essential to prevent cold weather injuries and mitigate their adverse impacts on military operations. Military training and combat operations require continued emphasis on effective cold weather injury prevention strategies and adherence to relevant policies and procedures to protect service members against such injuries.

lead to pulmonary edema, reduced heart rate, coma, ventricular arrhythmias (including ventricular fibrillation), and asystole.<sup>11-13</sup>

Peripheral cold injuries mainly affect extremities such as hands and feet, and can be further classified as either freezing injuries, such as frostbite, or non-freezing injuries such as immersion foot. Freezing peripheral injury is defined as the damage sustained by tissues exposed to temperatures below freezing.<sup>14</sup> A substantial proportion of patients with peripheral frostbite experience permanent changes in their microcirculation and disruption of local neurological functions (e.g., reduced sensation in the affected area).<sup>15</sup> The areas of the body most frequently affected by frostbite include the ears, nose, cheeks, chin, fingers, and toes.<sup>15,16</sup> Although most frostbite damage is minor, severe injury may lead to impaired functioning and inability to work due to cold hypersensitivity, chronic ulceration, vasospasm, localized osteoarthritis, or chronic pain.<sup>15,17</sup>

Non-freezing peripheral cold injury includes a spectrum of localized injuries to the soft tissues, nerves, and vasculature of distal extremities that result from prolonged exposure (12 to 48 hours) to wet, cold (generally 32 to 59°F) conditions; the injury process is generally slower in warmer water.<sup>14,21</sup> Although non-freezing peripheral cold injuries most often involve feet (e.g., immersion foot), any dependent body part can be affected by the condition, including the hands.<sup>22</sup> Immersion foot generally presents as waterlogging, with the most marked effect in the soles<sup>20,21</sup>. The foot becomes hyperemic (i.e., increased blood flow), painful, and swollen with continuous exposure; progression to blistering, decreased blood flow, ulceration, and gangrene is gradual.<sup>20,21</sup> Long-term complications of non-freezing cold injury such as immersion foot are similar to, and equally debilitating as, those produced by frostbite: hypersensitivity to cold, chronic pain, and severe pain induced by walking.<sup>17,19,20,21</sup>

Environmental factors that increase the risk of cold weather injuries include prolonged outdoor exposure to temperatures 40°F and below, wind speeds exceeding 5 miles per hour, high altitude, hypoxia, geographic location, wet conditions due to rain and snow, or submersion in cold water, in addition to lack of adequate shelter and clothing.<sup>22</sup> Situational factors that increase risk of immersion foot include immobility, wet socks, and constrictive boots.<sup>20,23,24</sup> Individual risk factors vary and include previous cold injury, exhaustion, dehydration, fatigue, sleep deprivation, improper acclimatization, inadequate nutrition, alcohol use, smoking, chronic disease (e.g., peripheral vascular disease, diabetes), older age, and medications that impair compensatory responses (e.g., oral antihyperglycemics, beta-blockers, general anesthetic agents).<sup>13-17,20</sup>

Since 2004, the *MSMR* has published annual updates on the incidence of cold weather injuries affecting U.S. military members for the 5 most recent cold seasons.<sup>25</sup> The timing of these annual updates is intended to call attention to the recurring risks of such injuries as winter approaches in the Northern Hemisphere, where most members of the U.S. Armed Forces are assigned. This 2023 report addresses the

occurrence of frostbite, immersion hand and foot, and hypothermia during the cold seasons from July 2018 through June 2023. Cases of chilblains are not included in this report because the condition is common, infrequently diagnosed, usually mild in severity, and thought to have minimal medical, public health, or military impacts.

Methods

This surveillance population included all individuals who served in the active or reserve components of the U.S. Armed Forces at any time during the surveillance period of July 1, 2018 through June 30, 2023. Service members in the Space Force were classified as Air Force for this analysis due to data availability beginning January 2023 for the newly formed service. For analysis purposes, “cold years” or “cold seasons” were defined as July 1 through June 30 intervals so complete cold weather seasons could be represented in annual summaries and comparisons.

Records of cold weather injuries for frostbite, immersion hand and foot, and hypothermia were queried from RMEs submitted to the Disease Reporting System internet (DRSi) and diagnostic codes from inpatient and outpatient medical encounters and records from the Theater Medical Data Store. Data from these sources are routinely incorporated into the Defense Medical Surveillance System (DMSS). A case was defined by the presence of an RME or 1 of any qualifying International Classification of Diseases, 9th or 10th revision (ICD-9 and ICD-10, respectively) code in the first diagnostic position of a record of a health care encounter (Table 1). Due to an update to the

DRSi medical event reporting system in July 2017, the type of RME for a cold injury (e.g., frostbite, immersion injury, hypothermia) could not be distinguished using RME records in DMSS data. Instead, information on the types of RMEs for cold injury between July 2018 and June 2023 were extracted from DRSi and then combined with DMSS data.

To estimate the number of unique individuals who suffered a cold injury each cold season, and to avoid counting follow-up health care encounters, only 1 cold injury per individual per cold season was included. To count types of cold injury, namely frostbite, immersion hand and foot, and hypothermia cases, 1 of each type of cold injury per individual per cold season could be included. For example, if an individual was diagnosed or reported with immersion hand and foot at 1 point during a cold season and then with frostbite later in the same cold season, each of those different types of injury would be included in the injury calculation. If a service member had multiple medical encounters for cold injuries on the same day, only 1 encounter was used for analysis (hospitalizations were prioritized over ambulatory visits, which were prioritized over RMEs).

Annual incidence rates of cold injuries among active component service members (ACSM) were calculated as incident cold injury diagnoses per 100,000 person-years (p-yrs) of service. Annual rates of cold injuries among reservists were calculated as cases per 100,000 persons using the total number of reserve component service members for each year of the surveillance period. Counts of persons in the reserves were used as the denominator in these calculations because information on the start and end dates of active duty service periods of reserve component members is not available.

TABLE 1. ICD-9/ICD-10 Diagnostic Codes for Cold Weather Injuries

| Case classification     | ICD-9                      | ICD-10 <sup>a</sup> |
|-------------------------|----------------------------|---------------------|
| Frostbite               | 991.0, 991.1, 991.2, 991.3 | T33.*, T34.*        |
| Immersion hand and foot | 991.4                      | T69.0*              |
| Hypothermia             | 991.6                      | T68.*               |

Abbreviation: ICD, International Classification of Diseases, 9th and 10th revisions.  
<sup>a</sup>An asterisk (\*) indicates that any subsequent digit/character is included.

Cold injuries are summarized by the locations where service members were treated for those injuries, identified by a Defense Medical Information System Identifier (DMIS ID) of an encounter. Because such injuries can occur during field training, temporary duty, or outside usual duty stations, DMIS ID was used as a proxy for the location where the cold injury occurred.

## Results

### 2022–2023 cold season

From July 2022 through June 2023, a total of 423 members of the active (n=376) and reserve (n=47) components had at least 1 cold weather injury (Table 2). In the active component, Army members had the highest rate of any cold injury (n=231, 50.9 per

100,000 p-yrs) during the 2022–2023 cold season, followed by members of the Marine Corps (n=55, 32.2 per 100,000 p-yrs), Air Force (n=61, 18.9 per 100,000 p-yrs), and Navy (n=27, 8.1 per 100,000 p-yrs). Only 2 active component Coast Guard members were affected by cold weather injuries during the 2022–2023 cold season (5.1 per 100,000 p-yrs). One cold injury, frostbite, was recorded for a member of the Space Force (counted with the Air Force) (data not shown). Among the reserve component, Army personnel accounted for more than two-thirds of cases (n=33, 6.1 per 100,000 p-yrs) during 2022–2023 (Table 2), although the Marine Corps had the highest rate of cold injuries among reservists (n=4, 10.2 per 100,000 persons).

When major types of cold injury case classifications are considered (not numbers of individuals affected), frostbite was the most common type of cold injury (n=202;

54.0% of all cold injuries) among ACSM in all services in 2022–2023 (Tables 3a–3e). Within the Air Force during the 2022–2023 season, 78.7% of all cold injuries were frostbite, but the proportions of frostbite injury in the Army (53.9%), Marine Corps (35.7%) and Navy (29.6%) were much lower. The Coast Guard had 2 cold weather injuries in 2022–2023, 1 each of frostbite and hypothermia.

For all active component service members in 2022–2023, the proportions of hypothermia (n=62) and immersion injuries (n=114) were 16.5% and 30.3%, respectively (Tables 3a–3e). The numbers and rates of hypothermia injuries in the 2022–2023 cold season were the lowest among active component Army and Marine Corps members during the 5-year period, while case counts and rates of frostbite were the lowest among active component Navy members (Table 3a, Table 3b, Table 3d).

**TABLE 2.** Annual Incidence of Service Members Affected by Any Cold Injury (1 per person per year), by Service and Component, July 2018–June 2023

|                                    | Army  |                   | Navy |                   | Air Force |                   | Marine Corps |                   | Coast Guard |                   | All services |                   |
|------------------------------------|-------|-------------------|------|-------------------|-----------|-------------------|--------------|-------------------|-------------|-------------------|--------------|-------------------|
|                                    | No.   | Rate <sup>a</sup> | No.  | Rate <sup>a</sup> | No.       | Rate <sup>a</sup> | No.          | Rate <sup>a</sup> | No.         | Rate <sup>a</sup> | No.          | Rate <sup>a</sup> |
| <b>Active component</b>            |       |                   |      |                   |           |                   |              |                   |             |                   |              |                   |
| All years (2018–2023)              | 1,323 | 56.5              | 135  | 8.1               | 275       | 16.9              | 404          | 45.1              | 11          | 5.5               | 2,148        | 31.9              |
| Jul 2018–Jun 2019                  | 275   | 59.1              | 22   | 6.7               | 46        | 14.3              | 118          | 63.9              | 4           | 9.7               | 465          | 34.7              |
| Jul 2019–Jun 2020                  | 234   | 49.4              | 28   | 8.4               | 48        | 14.6              | 59           | 32.0              | 1           | 2.5               | 370          | 27.2              |
| Jul 2020–Jun 2021                  | 298   | 62.4              | 26   | 7.6               | 57        | 17.3              | 99           | 55.0              | 2           | 5.0               | 482          | 35.3              |
| Jul 2021–Jun 2022                  | 285   | 60.4              | 32   | 9.4               | 63        | 19.4              | 73           | 41.3              | 2           | 5.0               | 455          | 33.6              |
| Jul 2022–Jun 2023                  | 231   | 50.9              | 27   | 8.1               | 61        | 18.9              | 55           | 32.2              | 2           | 5.1               | 376          | 28.5              |
| <b>Reserve component</b>           |       |                   |      |                   |           |                   |              |                   |             |                   |              |                   |
| All years (2018–2023)              | 190   |                   | 12   |                   | 46        |                   | 40           |                   | 3           |                   | 291          |                   |
| Jul 2018–Jun 2019                  | 45    | 7.8               | 1    | 1.6               | 7         | 3.7               | 16           | 35.4              | 0           | 0.0               | 69           | 7.8               |
| Jul 2019–Jun 2020                  | 36    | 6.2               | 2    | 3.1               | 10        | 5.3               | 4            | 9.0               | 0           | 0.0               | 52           | 5.9               |
| Jul 2020–Jun 2021                  | 42    | 7.3               | 6    | 9.5               | 13        | 6.9               | 11           | 25.6              | 1           | 15.1              | 73           | 8.3               |
| Jul 2021–Jun 2022                  | 34    | 6.0               | 2    | 3.2               | 7         | 3.7               | 5            | 11.9              | 2           | 30.3              | 50           | 5.8               |
| Jul 2022–Jun 2023                  | 33    | 6.1               | 1    | 1.7               | 9         | 4.9               | 4            | 10.2              | 0           | 0.0               | 47           | 5.7               |
| <b>Overall, active and reserve</b> |       |                   |      |                   |           |                   |              |                   |             |                   |              |                   |
| All years (2018–2023)              | 1,513 |                   | 147  |                   | 321       |                   | 444          |                   | 14          |                   | 2,439        |                   |
| Jul 2018–Jun 2019                  | 320   |                   | 23   |                   | 53        |                   | 134          |                   | 4           |                   | 534          |                   |
| Jul 2019–Jun 2020                  | 270   |                   | 30   |                   | 58        |                   | 63           |                   | 1           |                   | 422          |                   |
| Jul 2020–Jun 2021                  | 340   |                   | 32   |                   | 70        |                   | 110          |                   | 3           |                   | 555          |                   |
| Jul 2021–Jun 2022                  | 319   |                   | 34   |                   | 70        |                   | 78           |                   | 4           |                   | 505          |                   |
| Jul 2022–Jun 2023                  | 264   |                   | 28   |                   | 70        |                   | 59           |                   | 2           |                   | 423          |                   |

Abbreviation: No., number.

<sup>a</sup>For active component, rate is per 100,000 person-years; for reserve component, rate is per 100,000 persons.



## Five cold seasons: July 2018–June 2023

The crude overall incidence rate of cold injury for all ACSM in 2022–2023 was 28.5 per 100,000 p-yrs, representing a 15.2% decline compared to the rate observed in 2021–2022 (33.6 per 100,000 p-yrs) (Table 2, Figure 1). Throughout the surveillance period, cold injury rates were consistently higher among active component members of the Army and the Marine Corps (Figure 1). The active component service-specific incidence rates decreased the most from 2021–2022 to 2022–2023 among Marine Corps members, by 22.0%, followed by the Army, with a 15.8% decrease, while the Navy reported a 13.6% decrease, and the Air Force rate decreased 2.5%. Incidence rates of cold injuries for the last 2 cold seasons were similar for the Coast Guard (5.1 per 100,000 p-yrs in 2022–2023, 5.0 in 2021–2022). Crude overall incidence rates of cold injuries were also similar for reserve component service members (5.7 per 100,000 p-yrs in 2022–2023 and 5.8 per 100,000 p-yrs in 2021–2022) for the past 2 seasons (Figure 2).


During the 5-year surveillance period, overall rates of cold injuries were generally higher among males in all services except the Coast Guard (Tables 3a–3e). The overall rates among male service members of the Navy, Air Force, and Marine Corps were 1.6 to 1.8 times higher than those of their female counterparts.

For all services, overall rates of cold injuries were higher among non-Hispanic Black service members than those of the other races and ethnicities (Tables 3a–3e). Rates of frostbite among non-Hispanic Black members of the Army were more than 3 times higher than those of other races and ethnicities, with the biggest differences observed in the Marine Corps—where it was more than 4 times higher.

Rates of cold injuries in all services were highest among the youngest service members and tended to decrease with increasing age (Tables 3a–3e).


Enlisted members of all 5 services experienced higher rates of injury than officers. Rates of all cold injuries in the Army, Air Force, and Marine Corps combined were highest among service members in combat-specific (infantry/artillery/combat

**FIGURE 1.** Annual Incidence Rates of Service Members Affected by Any Cold Injury (1 per person per year), by Service, Active Component, U.S. Armed Forces, July 2018–June 2023



Abbreviation: P-yrs, person-years.

**FIGURE 2.** Annual Incidence Rates of Service Members Affected by Any Cold Injury (1 per person per year), by Service, Reserve Component, U.S. Armed Forces, July 2018–June 2023



Abbreviation: P-yrs, person-years.

or engineering/armor) occupations (Tables 3a, 3c–3d). Among the active component of the Navy, rates of cold injuries during the 5-year surveillance period were highest for service members in motor transport occupations (Table 3b).

Among the cold injury cases reported within the active component during the 5-year period ( $n=2,137$ ), 89 (4.2% of the total) occurred during basic training. The Army ( $n=36$ ) and Marine Corps ( $n=51$ ) accounted for 97.8% of all basic trainees

affected by cold injuries (**data not shown**). Throughout the course of the 5-year surveillance period, a total of 46 service members were hospitalized, a figure which represents 2.2% of total cold weather injuries for the period: Army (n=32) and Marine Corps (n=9) members accounted for most (89.1%) of all hospitalized cases (**data not shown**).

### Cold injuries during deployments

During the 5-year surveillance period a total of 66 cold injuries were diagnosed among service members deployed outside the U.S. (**data not shown**), of which 35 (53.0%) were frostbite, 20 (30.3%) were immersion injuries, and 11 (16.7%) were hypothermia. Approximately one-third (n=23) of all 66 deployment-associated

cold injuries were diagnosed during the 2018-2019 cold season. The number of cases in subsequent cold seasons were consistent, with 10 to 12 cold injuries recorded each season (**data not shown**). Frostbite injuries accounted for half (n=5; 50.0%) of cold weather injuries identified in service members deployed outside of the U.S during the 2022-2023 cold season.

**TABLE 3a.** Annual Incidence of Frostbite, Immersion Foot, and Hypothermia Among All Cold Injuries (1 type per person per year), Active Component, U.S. Army, July 2018–June 2023

|                                             | Frostbite |                   | Immersion foot |                   | Hypothermia |                   | All cold injuries |                   |
|---------------------------------------------|-----------|-------------------|----------------|-------------------|-------------|-------------------|-------------------|-------------------|
|                                             | No.       | Rate <sup>a</sup> | No.            | Rate <sup>a</sup> | No.         | Rate <sup>a</sup> | No.               | Rate <sup>a</sup> |
| Total                                       | 753       | 32.1              | 424            | 18.1              | 195         | 8.3               | 1,372             | 58.6              |
| <b>Sex</b>                                  |           |                   |                |                   |             |                   |                   |                   |
| Male                                        | 644       | 32.5              | 371            | 18.7              | 176         | 8.9               | 1,191             | 60.1              |
| Female                                      | 109       | 30.3              | 53             | 14.7              | 19          | 5.3               | 181               | 50.2              |
| <b>Race and ethnicity</b>                   |           |                   |                |                   |             |                   |                   |                   |
| White, non-Hispanic                         | 260       | 20.8              | 192            | 15.3              | 93          | 7.4               | 545               | 43.5              |
| Black, non-Hispanic                         | 348       | 73.4              | 158            | 33.3              | 61          | 12.9              | 567               | 119.5             |
| Other                                       | 145       | 23.6              | 74             | 12.0              | 41          | 6.7               | 260               | 42.2              |
| <b>Age</b>                                  |           |                   |                |                   |             |                   |                   |                   |
| <20                                         | 72        | 45.8              | 57             | 36.3              | 20          | 12.7              | 149               | 94.8              |
| 20-24                                       | 312       | 43.2              | 212            | 29.4              | 106         | 14.7              | 630               | 87.3              |
| 25-29                                       | 155       | 27.9              | 83             | 14.9              | 49          | 8.8               | 287               | 51.7              |
| 30-34                                       | 104       | 28.1              | 38             | 10.3              | 12          | 3.2               | 154               | 41.7              |
| 35-39                                       | 60        | 21.3              | 20             | 7.1               | 4           | 1.4               | 84                | 29.9              |
| 40-44                                       | 26        | 16.9              | 8              | 5.2               | 3           | 2.0               | 37                | 24.1              |
| 45+                                         | 24        | 23.1              | 6              | 5.8               | 1           | 1.0               | 31                | 29.8              |
| <b>Rank</b>                                 |           |                   |                |                   |             |                   |                   |                   |
| Enlisted                                    | 663       | 35.3              | 391            | 20.8              | 178         | 9.5               | 1,232             | 65.6              |
| Officer                                     | 90        | 19.3              | 33             | 7.1               | 17          | 3.7               | 140               | 30.1              |
| <b>Occupation</b>                           |           |                   |                |                   |             |                   |                   |                   |
| Infantry/artillery/armor/combat engineering | 287       | 49.0              | 191            | 32.6              | 100         | 17.1              | 578               | 98.7              |
| Motor transport                             | 23        | 31.6              | 13             | 17.8              | 4           | 5.5               | 40                | 54.9              |
| Repair/engineering                          | 124       | 26.2              | 75             | 15.8              | 31          | 6.5               | 230               | 48.5              |
| Communications/intelligence                 | 171       | 29.6              | 87             | 15.1              | 30          | 5.2               | 288               | 49.9              |
| Health care                                 | 51        | 22.1              | 18             | 7.8               | 9           | 3.9               | 78                | 33.7              |
| Other                                       | 97        | 24.1              | 40             | 10.0              | 21          | 5.2               | 158               | 39.3              |
| <b>Cold year (July-June)</b>                |           |                   |                |                   |             |                   |                   |                   |
| 2018-2019                                   | 143       | 30.7              | 106            | 22.8              | 41          | 8.8               | 290               | 62.3              |
| 2019-2020                                   | 115       | 24.3              | 94             | 19.8              | 47          | 9.9               | 256               | 54.0              |
| 2020-2021                                   | 181       | 37.9              | 81             | 17.0              | 38          | 8.0               | 300               | 62.8              |
| 2021-2022                                   | 189       | 40.1              | 67             | 14.2              | 38          | 8.1               | 294               | 62.3              |
| 2022-2023                                   | 125       | 27.5              | 76             | 16.7              | 31          | 6.8               | 232               | 51.1              |

Abbreviation: No., number.

<sup>a</sup>Rate per 100,000 person-years.

## Cold injuries by location

During the 5-year period, 20 military locations reported at least 25 incident cold injuries (1 per person per year) among ACSM (**Figure 3**). Locations with the highest 5-year counts of incident injuries were Fort Wainwright (n=236), Joint Base Elmendorf-Richardson (n=167), Fort Carson (n=96), Camp Lejeune (n=93), Fort

Moore (formerly Benning) (n=79), Fort Drum (n=71), and Fort Campbell (n=71) (**data not shown**). During the 2022-2023 cold season, incidence rates of cold injuries were higher than the 2021-2022 incidence rates at 6 of the 20 locations (**data not shown**). The most notable increase was at the Army's Fort Carson, where 22 cases (98.2 per 100,000 p-yrs) were identified in 2022-2023, compared to 11 (42.1

per 100,000 p-yrs) the prior year (**data not shown**). U.S. Army Garrison Bavaria's case count increased the most, from 1 in 2021-2022 to 40 in 2022-2023. **Figure 3** charts the 2022-2023 seasonal numbers of cold injuries and median case numbers for the prior 4 seasons for the 20 locations with at least 25 cases. At 16 installations, case numbers in 2022-2023 were less than the median counts for the previous 4 years.

**TABLE 3b.** Annual Incidence of Frostbite, Immersion foot, and Hypothermia Among All Cold Injuries (1 type per person per year), Active Component, U.S. Navy, July 2018–June 2023

|                                             | Frostbite |                   | Immersion foot |                   | Hypothermia |                   | All cold injuries |                   |
|---------------------------------------------|-----------|-------------------|----------------|-------------------|-------------|-------------------|-------------------|-------------------|
|                                             | No.       | Rate <sup>a</sup> | No.            | Rate <sup>a</sup> | No.         | Rate <sup>a</sup> | No.               | Rate <sup>a</sup> |
| Total                                       | 59        | 3.5               | 25             | 1.5               | 51          | 3.0               | 135               | 8.1               |
| <b>Sex</b>                                  |           |                   |                |                   |             |                   |                   |                   |
| Male                                        | 51        | 3.8               | 23             | 1.7               | 44          | 3.3               | 118               | 8.9               |
| Female                                      | 8         | 2.4               | 2              | 0.6               | 7           | 2.1               | 17                | 5.0               |
| <b>Race and ethnicity</b>                   |           |                   |                |                   |             |                   |                   |                   |
| White, non-Hispanic                         | 27        | 3.2               | 9              | 1.1               | 28          | 3.4               | 64                | 7.7               |
| Black, non-Hispanic                         | 17        | 6.5               | 8              | 3.1               | 8           | 3.1               | 33                | 12.6              |
| Other                                       | 15        | 2.6               | 8              | 1.4               | 15          | 2.6               | 38                | 6.6               |
| <b>Age</b>                                  |           |                   |                |                   |             |                   |                   |                   |
| <20                                         | 3         | 3.1               | 3              | 3.1               | 7           | 7.2               | 13                | 13.3              |
| 20-24                                       | 18        | 3.6               | 9              | 1.8               | 21          | 4.2               | 48                | 9.7               |
| 25-29                                       | 25        | 6.1               | 3              | 0.7               | 18          | 4.4               | 46                | 11.3              |
| 30-34                                       | 6         | 2.1               | 2              | 0.7               | 3           | 1.0               | 11                | 3.8               |
| 35-39                                       | 2         | 1.0               | 3              | 1.4               | 2           | 1.0               | 7                 | 3.3               |
| 40-44                                       | 1         | 0.9               | 4              | 3.7               | 0           | 0.0               | 5                 | 4.6               |
| 45+                                         | 4         | 6.1               | 1              | 1.5               | 0           | 0.0               | 5                 | 7.6               |
| <b>Rank</b>                                 |           |                   |                |                   |             |                   |                   |                   |
| Enlisted                                    | 47        | 3.4               | 22             | 1.6               | 47          | 3.4               | 116               | 8.3               |
| Officer                                     | 12        | 4.3               | 3              | 1.1               | 4           | 1.4               | 19                | 6.8               |
| <b>Occupation</b>                           |           |                   |                |                   |             |                   |                   |                   |
| Infantry/artillery/armor/combat engineering | 3         | 2.9               | 0              | 0.0               | 3           | 2.9               | 6                 | 5.8               |
| Motor transport                             | 2         | 3.0               | 0              | 0.0               | 17          | 25.3              | 19                | 28.3              |
| Repair/engineering                          | 15        | 2.0               | 8              | 1.1               | 13          | 1.8               | 36                | 4.9               |
| Communications/intelligence                 | 8         | 3.0               | 7              | 2.6               | 4           | 1.5               | 19                | 7.1               |
| Health care                                 | 16        | 9.0               | 0              | 0.0               | 3           | 1.7               | 19                | 10.7              |
| Other                                       | 15        | 4.7               | 10             | 3.1               | 11          | 3.4               | 36                | 11.2              |
| <b>Cold year (July-June)</b>                |           |                   |                |                   |             |                   |                   |                   |
| 2018-2019                                   | 16        | 4.9               | 1              | 0.3               | 5           | 1.5               | 22                | 6.7               |
| 2019-2020                                   | 14        | 4.2               | 6              | 1.8               | 8           | 2.4               | 28                | 8.4               |
| 2020-2021                                   | 10        | 2.9               | 3              | 0.9               | 13          | 3.8               | 26                | 7.6               |
| 2021-2022                                   | 11        | 3.2               | 8              | 2.3               | 13          | 3.8               | 32                | 9.4               |
| 2022-2023                                   | 8         | 2.4               | 7              | 2.1               | 12          | 3.6               | 27                | 8.1               |

Abbreviation: No., number.

<sup>a</sup>Rate per 100,000 person-years.

## Discussion

The overall rate of cold weather injuries among ACSM in 2022-2023 decreased by 15.2% from the previous cold injury season. This decrease was most pronounced within the Marine Corps, with a 22.0% lower incidence rate from 2021-2022.

As in prior years, cold injury rates were much higher among members of the Army and Marine Corps. In 2022-2023, frostbite was the most common type of cold injury among ACSM in all 5 services.

Compared to their respective counterparts, overall rates of cold injuries were higher among male service members, non-Hispanic Black service members,

the youngest (less than 20 years old), and enlisted service members. Rates of frostbite were markedly higher among non-Hispanic Blacks compared to non-Hispanic Whites and those in the other/unknown race and ethnicity group. These differences have been noted in prior *MSMR* updates, and results of several studies suggest that other factors (e.g., physiological differences,

**TABLE 3c.** Annual Incidence of Frostbite, Immersion Foot, and Hypothermia Among All Cold Injuries (1 type per person per year), Active Component, U.S. Air Force, July 2018–June 2023

|                                             | Frostbite |                   | Immersion foot |                   | Hypothermia |                   | All cold injuries |                   |
|---------------------------------------------|-----------|-------------------|----------------|-------------------|-------------|-------------------|-------------------|-------------------|
|                                             | No.       | Rate <sup>a</sup> | No.            | Rate <sup>a</sup> | No.         | Rate <sup>a</sup> | No.               | Rate <sup>a</sup> |
| Total                                       | 227       | 14.0              | 16             | 1.0               | 35          | 2.2               | 278               | 17.1              |
| <b>Sex</b>                                  |           |                   |                |                   |             |                   |                   |                   |
| Male                                        | 198       | 15.5              | 13             | 1.0               | 28          | 2.2               | 239               | 18.7              |
| Female                                      | 29        | 8.5               | 3              | 0.9               | 7           | 2.1               | 39                | 11.4              |
| <b>Race and ethnicity</b>                   |           |                   |                |                   |             |                   |                   |                   |
| White, non-Hispanic                         | 123       | 12.9              | 7              | 0.7               | 21          | 2.2               | 151               | 15.8              |
| Black, non-Hispanic                         | 55        | 24.8              | 4              | 1.8               | 6           | 2.7               | 65                | 29.3              |
| Other                                       | 49        | 11.1              | 5              | 1.1               | 8           | 1.8               | 62                | 14.0              |
| <b>Age</b>                                  |           |                   |                |                   |             |                   |                   |                   |
| <20                                         | 18        | 24.2              | 2              | 2.7               | 4           | 5.4               | 24                | 32.2              |
| 20-24                                       | 119       | 25.8              | 10             | 2.2               | 12          | 2.6               | 141               | 30.6              |
| 25-29                                       | 39        | 9.7               | 2              | 0.5               | 10          | 2.5               | 51                | 12.7              |
| 30-34                                       | 24        | 7.9               | 0              | 0.0               | 6           | 2.0               | 30                | 9.9               |
| 35-39                                       | 17        | 7.3               | 2              | 0.9               | 1           | 0.4               | 20                | 8.6               |
| 40-44                                       | 3         | 2.9               | 0              | 0.0               | 1           | 1.0               | 4                 | 3.9               |
| 45+                                         | 7         | 15.2              | 0              | 0.0               | 1           | 2.2               | 8                 | 17.4              |
| <b>Rank</b>                                 |           |                   |                |                   |             |                   |                   |                   |
| Enlisted                                    | 206       | 15.8              | 15             | 1.1               | 29          | 2.2               | 250               | 19.1              |
| Officer                                     | 21        | 6.7               | 1              | 0.3               | 6           | 1.9               | 28                | 8.9               |
| <b>Occupation</b>                           |           |                   |                |                   |             |                   |                   |                   |
| Infantry/artillery/armor/combat engineering | 10        | 81.5              | 0              | 0.0               | 0           | 0.0               | 10                | 81.5              |
| Motor transport                             | 0         | 0.0               | 0              | 0.0               | 0           | 0.0               | 0                 | 0.0               |
| Repair/engineering                          | 90        | 17.9              | 6              | 1.2               | 8           | 1.6               | 104               | 20.6              |
| Communications/intelligence                 | 35        | 10.2              | 1              | 0.3               | 5           | 1.5               | 41                | 11.9              |
| Health care                                 | 9         | 6.0               | 1              | 0.7               | 2           | 1.3               | 12                | 8.0               |
| Other                                       | 83        | 13.9              | 8              | 1.3               | 20          | 3.3               | 111               | 18.5              |
| <b>Cold year (July-June)</b>                |           |                   |                |                   |             |                   |                   |                   |
| 2018-2019                                   | 40        | 12.4              | 2              | 0.6               | 5           | 1.6               | 47                | 14.6              |
| 2019-2020                                   | 39        | 11.9              | 2              | 0.6               | 8           | 2.4               | 49                | 14.9              |
| 2020-2021                                   | 47        | 14.3              | 1              | 0.3               | 9           | 2.7               | 57                | 17.3              |
| 2021-2022                                   | 53        | 16.3              | 5              | 1.5               | 6           | 1.8               | 64                | 19.7              |
| 2022-2023                                   | 48        | 15.1              | 6              | 1.9               | 7           | 2.2               | 61                | 19.2              |

Abbreviation: No., number.

<sup>a</sup>Rate per 100,000 person-years.



previous cold weather experience) are possible explanations for increased susceptibility.<sup>9,15,26–28</sup>

It should be noted that this analysis of cold injuries was unable to distinguish between injuries sustained during official military duties (training or operations) and those associated with unrelated or personal activities. RMEs for non-freezing

peripheral injuries were excluded if “chilblains” was listed in case comments; some RMEs for chilblains were potentially misclassified, however, as immersion injury if chilblains were not listed in the case comments.

To prepare for all circumstances posing a threat for cold weather injury, service members should be aware of and able to

identify signs of cold injury, as well as environmental, individual and situational risk factors, and protective measures for themselves and fellow service members, whether during training, operations, combat, or recreation in wet or freezing conditions.

*This article has been revised due to an error in the original published version.*

**TABLE 3d.** Annual Incidence of Frostbite, Immersion Hand and Foot, and Hypothermia Among All Cold Injuries (1 type per person per year), Active Component, U.S. Marines, July 2018–June 2023

|                                             | Frostbite |                   | Immersion foot |                   | Hypothermia |                   | All cold injuries |                   |
|---------------------------------------------|-----------|-------------------|----------------|-------------------|-------------|-------------------|-------------------|-------------------|
|                                             | No.       | Rate <sup>a</sup> | No.            | Rate <sup>a</sup> | No.         | Rate <sup>a</sup> | No.               | Rate <sup>a</sup> |
| Total                                       | 190       | 21.2              | 124            | 13.8              | 95          | 10.6              | 409               | 45.6              |
| <b>Sex</b>                                  |           |                   |                |                   |             |                   |                   |                   |
| Male                                        | 183       | 22.4              | 117            | 14.3              | 85          | 10.4              | 385               | 47.2              |
| Female                                      | 7         | 8.6               | 7              | 8.6               | 10          | 12.3              | 24                | 29.6              |
| <b>Race and ethnicity</b>                   |           |                   |                |                   |             |                   |                   |                   |
| White, non-Hispanic                         | 89        | 17.2              | 75             | 14.5              | 44          | 8.5               | 208               | 40.3              |
| Black, non-Hispanic                         | 62        | 70.0              | 8              | 9.0               | 20          | 22.6              | 90                | 101.6             |
| Other                                       | 39        | 13.3              | 41             | 14.0              | 31          | 10.6              | 111               | 38.0              |
| <b>Age</b>                                  |           |                   |                |                   |             |                   |                   |                   |
| <20                                         | 21        | 17.4              | 57             | 47.2              | 28          | 23.2              | 106               | 87.8              |
| 20-24                                       | 117       | 27.2              | 52             | 12.1              | 52          | 12.1              | 221               | 51.4              |
| 25-29                                       | 31        | 19.7              | 11             | 7.0               | 11          | 7.0               | 53                | 33.6              |
| 30-34                                       | 15        | 18.2              | 4              | 4.8               | 3           | 3.6               | 22                | 26.6              |
| 35-39                                       | 6         | 9.6               | 0              | 0.0               | 0           | 0.0               | 6                 | 9.6               |
| 40-44                                       | 0         | 0.0               | 0              | 0.0               | 1           | 3.6               | 1                 | 3.6               |
| 45+                                         | 0         | 0.0               | 0              | 0.0               | 0           | 0.0               | 0                 | 0.0               |
| <b>Rank</b>                                 |           |                   |                |                   |             |                   |                   |                   |
| Enlisted                                    | 165       | 20.9              | 113            | 14.3              | 88          | 11.2              | 366               | 46.4              |
| Officer                                     | 25        | 23.1              | 11             | 10.2              | 7           | 6.5               | 43                | 39.7              |
| <b>Occupation</b>                           |           |                   |                |                   |             |                   |                   |                   |
| Infantry/artillery/armor/combat engineering | 114       | 58.7              | 16             | 8.2               | 38          | 19.6              | 168               | 86.6              |
| Motor transport                             | 3         | 6.9               | 1              | 2.3               | 2           | 4.6               | 6                 | 13.8              |
| Repair/engineering                          | 14        | 6.5               | 13             | 6.0               | 4           | 1.8               | 31                | 14.3              |
| Communications/intelligence                 | 31        | 14.5              | 11             | 5.1               | 8           | 3.7               | 50                | 23.4              |
| Health care                                 | 0         | 0.0               | 0              | 0.0               | 0           | 0.0               | 0                 | 0.0               |
| Other                                       | 28        | 12.3              | 83             | 36.4              | 43          | 18.8              | 154               | 67.5              |
| <b>Cold year (July-June)</b>                |           |                   |                |                   |             |                   |                   |                   |
| 2018-2019                                   | 54        | 29.3              | 36             | 19.5              | 30          | 16.3              | 120               | 65.0              |
| 2019-2020                                   | 26        | 14.1              | 15             | 8.1               | 18          | 9.8               | 59                | 32.0              |
| 2020-2021                                   | 57        | 31.6              | 24             | 13.3              | 18          | 10.0              | 99                | 55.0              |
| 2021-2022                                   | 33        | 18.7              | 24             | 13.6              | 18          | 10.2              | 75                | 42.4              |
| 2022-2023                                   | 20        | 11.7              | 25             | 14.6              | 11          | 6.4               | 56                | 32.8              |

Abbreviation: No., number.

<sup>a</sup>Rate per 100,000 person-years.

**TABLE 3e.** Annual Incidence of Frostbite, Immersion Foot, and Hypothermia Among All Cold Injuries (1 type per person per year), Active Component, U.S. Coast Guard, July 2018–June 2023

|                                             | Frostbite |                   | Immersion foot |                   | Hypothermia |                   | All cold injuries |                   |
|---------------------------------------------|-----------|-------------------|----------------|-------------------|-------------|-------------------|-------------------|-------------------|
|                                             | No.       | Rate <sup>a</sup> | No.            | Rate <sup>a</sup> | No.         | Rate <sup>a</sup> | No.               | Rate <sup>a</sup> |
| Total                                       | 8         | 4.0               | 0              | 0.0               | 3           | 1.5               | 11                | 5.5               |
| Sex                                         |           |                   |                |                   |             |                   |                   |                   |
| Male                                        | 7         | 4.1               | 0              | 0.0               | 2           | 1.2               | 9                 | 5.3               |
| Female                                      | 1         | 3.2               | 0              | 0.0               | 1           | 3.2               | 2                 | 6.5               |
| Race and ethnicity                          |           |                   |                |                   |             |                   |                   |                   |
| White, non-Hispanic                         | 7         | 5.4               | 0              | 0.0               | 2           | 1.6               | 9                 | 7.0               |
| Black, non-Hispanic                         | 0         | 0.0               | 0              | 0.0               | 1           | 9.8               | 1                 | 9.8               |
| Other                                       | 1         | 1.6               | 0              | 0.0               | 0           | 0.0               | 1                 | 1.6               |
| Age                                         |           |                   |                |                   |             |                   |                   |                   |
| <20                                         | 0         | 0.0               | 0              | 0.0               | 0           | 0.0               | 0                 | 0.0               |
| 20-24                                       | 1         | 2.4               | 0              | 0.0               | 1           | 2.4               | 2                 | 4.8               |
| 25-29                                       | 3         | 7.3               | 0              | 0.0               | 2           | 4.9               | 5                 | 12.2              |
| 30-34                                       | 2         | 5.0               | 0              | 0.0               | 0           | 0.0               | 2                 | 5.0               |
| 35-39                                       | 1         | 2.6               | 0              | 0.0               | 0           | 0.0               | 1                 | 2.6               |
| 40-44                                       | 1         | 4.5               | 0              | 0.0               | 0           | 0.0               | 1                 | 4.5               |
| 45+                                         | 0         | 0.0               | 0              | 0.0               | 0           | 0.0               | 0                 | 0.0               |
| Rank                                        |           |                   |                |                   |             |                   |                   |                   |
| Enlisted                                    | 8         | 5.1               | 0              | 0.0               | 3           | 1.9               | 11                | 7.0               |
| Officer                                     | 0         | 0.0               | 0              | 0.0               | 0           | 0.0               | 0                 | 0.0               |
| Occupation                                  |           |                   |                |                   |             |                   |                   |                   |
| Infantry/artillery/armor/combat engineering | 0         | 0.0               | 0              | 0.0               | 0           | 0.0               | 0                 | 0.0               |
| Motor transport                             | 2         | 7.7               | 0              | 0.0               | 0           | 0.0               | 2                 | 7.7               |
| Repair/engineering                          | 4         | 6.3               | 0              | 0.0               | 1           | 1.6               | 5                 | 7.9               |
| Communications/intelligence                 | 1         | 3.4               | 0              | 0.0               | 2           | 6.9               | 3                 | 10.3              |
| Health care                                 | 0         | 0.0               | 0              | 0.0               | 0           | 0.0               | 0                 | 0.0               |
| Other                                       | 1         | 1.3               | 0              | 0.0               | 0           | 0.0               | 1                 | 1.3               |
| Cold year (July-June)                       |           |                   |                |                   |             |                   |                   |                   |
| 2018-2019                                   | 4         | 9.7               | 0              | 0.0               | 0           | 0.0               | 4                 | 9.7               |
| 2019-2020                                   | 1         | 2.5               | 0              | 0.0               | 0           | 0.0               | 1                 | 2.5               |
| 2020-2021                                   | 1         | 2.5               | 0              | 0.0               | 1           | 2.5               | 2                 | 5.0               |
| 2021-2022                                   | 1         | 2.5               | 0              | 0.0               | 1           | 2.5               | 2                 | 5.0               |
| 2022-2023                                   | 1         | 2.6               | 0              | 0.0               | 1           | 2.6               | 2                 | 5.1               |


Abbreviation: No., number.

<sup>a</sup>Rate per 100,000 person-years.

## References

- Candler WH, Freedman MS. Military medical operations in cold environments. In: Pandolf KB, Burr RE, eds. *Medical Aspects of Harsh Environments, Volume 1*. Office of the Surgeon General; 2001:553-566.
- Paton BC. Cold, casualties, and conquests: the effects of cold on warfare. In: Pandolf KB, Burr RE, eds. *Medical Aspects of Harsh Environments, Volume 1*. Office of the Surgeon General; 2001:313-349.
- Pozos RS (ed.). Section II: cold environments. In: Pandolf KB, Burr RE, eds. *Medical Aspects of Harsh Environments, Volume 1*. Office of the Surgeon General; 2001:311-566.
- DeGroot DW, Castellani JW, Williams JO, Amoroso PJ. Epidemiology of U.S. Army cold weather injuries, 1980–1999. *Aviat Space Environ Med*. 2003;74(5):564-570.
- Headquarters, Department of the Army. Technical Bulletin Medical 508. Prevention and Management of Cold-Weather Injuries. Apr. 1, 2005.
- Headquarters, Department of the Army, Training and Doctrine Command. TRADOC Regulation 350-29: Prevention of Heat and Cold Casualties. Jun. 15, 2023.
- Headquarters, Department of the Army, Training and Doctrine Command. TRADOC Regulation 350-6: Enlisted Initial Entry Training Policies and Administration. Aug. 9, 2019.
- Castellani JW, O'Brien C, Baker-Fulco C, Sawka MN, Young AJ. Sustaining health and

**FIGURE 3.** Annual Frequency (cold season 2022–2023) and Median Numbers (cold seasons 2018–2022) of Cold Injuries at Locations with at Least 25 Cold Injuries During the Surveillance Period, Active Component, U.S. Armed Forces, July 2018–June 2023



No., number; JB, Joint Base; USAG, U.S. Army Garrison; GER, Germany; AFB, Air Force Base; MCB, Marine Corps Base; MCRD, Marine Corps Recruit Depot.

performance in cold weather operations. Technical Note TN/02-2. U.S. Army Research Institute of Environmental Medicine. Oct. 2001.

9. Armed Forces Health Surveillance Branch. Update: cold weather injuries, active and reserve component, U.S. Armed Forces, July 2013–June 2018. *MSMR*. 2018;25(11):10-17.

10. Armed Forces Health Surveillance Branch. Armed Forces Reportable Events Guidelines and Case Definitions, 2020. <https://www.health.mil/Military-Health-Topics/Health-Readiness/AFHSD/Reports-and-Publications/Armed-Forces-Reportable-Medical-Events>

11. Jolly BT, Ghezzi KT. Accidental hypothermia. *Emerg Med Clin North Am*. 1992;10(2):311-327.

12. Rischall ML, Rowland-Fisher A. Evidence-based management of accidental hypothermia in the emergency department. *Emerg Med Pract*. 2016;18(1):1-18.

13. Biem J, Koehncke N, Classen D, Dosman J. Out of the cold: management of hypothermia and frostbite. *CMAJ*. 2003;168(3):305-311.

14. Imray CH, Oakley EH. Cold still kills: cold-related illnesses in military practice freezing and non-freezing cold injury. *J R Army Med Corps*. 2005;151(4):218-222. doi:10.1136/jramc-151-04-02

15. Ervasti O, Hassi J, Rintamaki H, et al. Se-

quelae of moderate finger frostbite as assessed by subjective sensations, clinical signs, and thermophysiological responses. *Int J Circumpolar Health*. 2000;59(2):137-145.

16. Harirchi I, Arvin A, Vash JH, Zafarmand V. Frostbite: incidence and predisposing factors in mountaineers. *Br J Sports Med*. 2005;39(12):898-901. doi:10.1136/bjism.2004.016097

17. Handford C, Thomas O, Imray CHE. Frostbite. *Emerg Med Clin North Am*. 2017;35(2):281-299.

18. Murphy JV, Banwell PE, Roberts AH, McGrouther DA. Frostbite: pathogenesis and treatment. *J Trauma*. 2000;48(1):171-178. doi:10.1097/00005373-200001000-00036

19. Petrone P, Kuncir EJ, Asensio JA. Surgical management and strategies in the treatment of hypothermia and cold injury. *Emerg Med Clin North Am*. 2003;21(4):1165-1178. doi:10.1016/s0733-8627(03)00074-9

20. Imray C, Grieve A, Dhillon S, Caudwell Xtreme Everest Research Group. Cold damage to the extremities: frostbite and non-freezing cold injuries. *Postgrad Med J*. 2009;85(1007):481-488. doi:10.1136/pgmj.2008.068635

21. Hall A, Sexton J, Lynch B, et al. Frostbite and immersion foot care. *Mil Med*. 2018;183(suppl 2):168-171. doi:10.1093/milmed/usy085

22. van Dongen TFCF, Berendsen RR, de Jong

FJM, et al. Frostbite: a systematic review on freezing cold injuries in a military environment. *BMJ Mil Health*. Epub. doi:10.1136/military-2022-002171

23. McMahon JA, Howe A. Cold weather issues in sideline and event management. *Curr Sports Med Rep*. 2012;11(3):135-141. doi:10.1249/JSR.0b013e3182578783

24. Centers for Disease Control and Prevention. Natural Disasters and Severe Weather: Trench Foot or Immersion Foot. <https://www.cdc.gov/disasters/trenchfoot.html>

25. Army Medical Surveillance Activity. Cold injuries, active duty, U.S. Armed Forces, July 1999–June 2004. *MSMR*. 2004;10(5):2-10.

26. Burgess JE, Macfarlane F. Retrospective analysis of the ethnic origins of male British Army soldiers with peripheral cold weather injury. *J R Army Med Corps*. 2009;155(1):11-15. doi:10.1136/jramc-155-01-04

27. Maley MJ, Eglin CM, House JR, Tipton MJ. The effect of ethnicity on the vascular responses to cold exposure of the extremities. *Eur J Appl Physiol*. 2014;114(11):2369-2379. doi:10.1007/s00421-014-2962-2

28. Kuht JA, Woods D, Hollis S. Case series of non-freezing cold injury: epidemiology and risk factors. *J R Army Med Corps*. 2019;165(6):400-404. doi:10.1136/jramc-2018-000992

# Clinically Diagnosed Sunburn Among Active Component Service Members, U.S. Armed Forces, 2014–2022

Lynn A. Van Airsdale, DO, MPH; Shauna Stahlman, PhD, MPH; Kayli Hiban, MPH; Natalie Y. Wells, MD, MPH

Sunburn affects U.S. military mission readiness, from clothing and gear discomfort, to infection and dehydration risk due to skin barrier breakdown and fluid loss.<sup>1</sup> Depending on a service member's military occupation, ultraviolet radiation (UVR) exposure will vary, as seen with higher incidences of sunburn in recruits, aircraft and aircraft-related occupations, and infantry.<sup>1</sup> Clinically, sunburn is classified and managed within 2 main categories: mild-moderate and severe.<sup>2</sup> Electronic health record (EHR) sunburn documentation is determined by International Classification of Diseases, 10<sup>th</sup> Revision (ICD-10) diagnosis codes that classify sunburn as sunburn of first degree, second degree, third degree, or unspecified. Sunburn of first degree (superficial burn) only affects the outer layer of the skin (epidermis), manifesting in mild to moderate erythema without blistering. Sunburn of second degree (partial thickness burn) affects both the epidermis and part of the dermis, resulting in erythema with blistering, with or without edema. Sunburn of third degree (full thickness burn) affects the epidermis and dermis, and occasionally the underlying bones, muscles, and tendons.

A significant cause of skin cancer is excessive UVR exposure, often in the form of repeated sunburn.<sup>3</sup> Among U.S. military service members, non-melanoma skin cancers (NMSC) are the most frequently diagnosed cancer.<sup>4,5</sup> Additionally, a recent Department of Defense (DOD) report found that U.S. military aircrew had an 87% higher rate of melanoma, and aviation support personnel (ground crew) had a 9% higher rate of melanoma, compared to the general U.S. population.<sup>6</sup>

A 2014 *MSMR* report documented 19,172 incident cases of clinically-diagnosed sunburn among active component service members of the U.S. military from

January 2002 to December 2013.<sup>1</sup> Incidence rates were higher among women, non-Hispanic White service members, and those in younger age groups. Additionally, incidence was also higher for those in the Marine Corps and Army, as well as enlisted members, and recruits.<sup>1</sup> This report describes recent frequencies and rates of clinically-diagnosed sunburn among active component service members (ACSM).

## Methods

This retrospective cohort study covered a surveillance period from January 1, 2014 to September 30, 2022 and included all ACSM of the U.S. Army, Air Force, Navy, and Marine Corps. Data were derived from the Defense Medical Surveillance System (DMSS), which is maintained by the Armed Forces Health Surveillance Division (AFHSD). DMSS documents ambulatory care encounters and hospitalizations in fixed military and civilian (if reimbursed through the Military Health System) treatment facilities worldwide.

Outcome of sunburn was identified through inpatient and outpatient medical encounters containing an ICD-9 code of 692.71 (sunburn of first degree), 692.76 (sunburn of second degree), 692.77 (sunburn of third degree), or an ICD-10 code of L55.0 (sunburn of first degree), L55.1 (sunburn of second degree), L55.2 (sunburn of third degree), or L55.9 (sunburn, unspecified), in the first or second diagnostic position. The transition between ICD-9 and ICD-10 codes, in 2015, occurred during the study's surveillance period.

An individual was classified as a new case of sunburn if at least 30 days passed since the documentation of a previous sunburn-associated medical encounter.

Incidence of sunburn was calculated per 100,000 person-years (p-yrs). Negative binomial regression calculated incidence rate ratios for occupation categories, adjusting for sex, age, and race and ethnicity.

## Results

**Table 1** provides the total incident case counts and crude incidence rates of clinically-diagnosed sunburn among ACSM during the 9-year surveillance period. Over half of the cases were first degree sunburn (n=6,244; 54.5%), and almost all cases were diagnosed in the ambulatory setting (n=12,029; 99.95%). During the 9-year surveillance period, most, 97.1% (n=11,687), reported cases had only 1 diagnosed sunburn.

The incidence rate of sunburn diagnosis was higher among women compared to men. Non-Hispanic White service members had the highest rate compared to other races and ethnicities. The 3 youngest age groups, under 20 years, 20–24, and 25–29 years of age, had the highest incidence rates of sunburn diagnosis, with rates decreasing with increasing age until 45 years of age. The Marine Corps and Army had the highest rates among the services. Recruits had a significantly higher sunburn incidence compared to non-recruit enlisted service members and officers.

The annual total sunburn incidence rates, which varied annually, increased overall 6.4% from 2014 (100.3 per 100,000) through 2022 (106.8 per 100,000). Of the 12,035 cases of sunburn, 5,542 occurred in June (46.0%), more than in any other month (**data not shown**). Ten military installations/regions accounted for 36% of all sunburns during the surveillance period. The highest overall counts were in Okinawa, Japan

(n=513) and San Diego, CA (n=510), followed closely by Fort Moore (formerly Benning), GA (n=468), and Fort Leonard Wood, MO (n=454) (data not shown).

**Table 2** provides the crude and adjusted rate ratios for the association between occupational category and sunburn. The pilot/air crew category had the lowest crude and adjusted incidence rate of sunburn diagnosis.

## Discussion

Compared to the prior *MSMR* report, the incidence of clinically-diagnosed sunburn among ACSM decreased 15.9% from 2002-2013 to 2014-2022 (from 124.8 cases per 100,000 p-yrs to 105.0 cases per 100,000 p-yrs).<sup>1</sup> In both studies, women demonstrated a higher rate of sunburn diagnosis. Epidemiological data of the general U.S. population suggest that women are less likely to report frequent sunburn and are more likely to implement sunburn prevention measures.<sup>7,8,9</sup> According to National Cancer Institute statistics, however, reported sunburn for women differs from men by age, with younger women (aged 18-24) accounting for a higher proportion of sunburns than men in the same age group.<sup>10</sup> The majority of ACSM are under 25 years of age, which could partially explain the higher incidence of sunburn among women described in this study.

Similar to the 2014 *MSMR* report, non-Hispanic White service members and younger age groups had higher diagnosed sunburn rates, which is consistent with the general U.S. population.<sup>7</sup> The current study found that pilot/air crew had the lowest rate of sunburn diagnosis, both before and after adjustment for potential confounders, which suggests that other factors such as differences in health care utilization or sunburn prevention measures may influence lower incidence of sunburn diagnoses.

One limitation of this study is outcome misclassification bias for sunburn diagnosis based upon health care utilization. This report likely underestimates the true rate of sunburn, as only individuals with more serious burns are likely to present for medical care. Additionally,

**TABLE 1.** Incident Counts and Rates of Sunburn by Severity, Demographic and Military Characteristics, Active Component, U.S. Armed Forces, 2014-2022<sup>a</sup>

|                                              | No.    | Rate <sup>b</sup> |
|----------------------------------------------|--------|-------------------|
| Total                                        | 12,035 | 105.0             |
| Type of sunburn                              |        |                   |
| First degree (ICD-9: 692.71; ICD-10: L55.0)  | 6,244  | 54.5              |
| Second degree (ICD-9: 692.76, ICD-10: L55.1) | 3,264  | 28.5              |
| Third degree (ICD-9: 692.77; ICD-10: L55.2)  | 27     | 0.2               |
| Unspecified (ICD-10: L55.9, L55)             | 2,500  | 21.8              |
| Sex                                          |        |                   |
| Male                                         | 9,608  | 100.2             |
| Female                                       | 2,427  | 129.4             |
| Race and ethnicity                           |        |                   |
| Non-Hispanic White                           | 10,212 | 157.8             |
| Non-Hispanic Black                           | 259    | 14.0              |
| Hispanic                                     | 866    | 47.6              |
| Other                                        | 553    | 49.9              |
| Unknown/missing                              | 145    | 69.6              |
| Age group, years                             |        |                   |
| <20                                          | 4,236  | 277.5             |
| 20-24                                        | 4,165  | 141.4             |
| 25-29                                        | 2,071  | 77.5              |
| 30-34                                        | 812    | 44.2              |
| 35-39                                        | 451    | 33.8              |
| 40-44                                        | 172    | 24.1              |
| 45+                                          | 128    | 29.8              |
| Service                                      |        |                   |
| Army                                         | 5,144  | 123.2             |
| Navy                                         | 2,061  | 71.7              |
| Air Force                                    | 2,558  | 91.3              |
| Marine Corps                                 | 2,272  | 141.4             |
| Rank                                         |        |                   |
| Recruit                                      | 1387   | 575.8             |
| Enlisted (non-recruit)                       | 9,949  | 108.3             |
| Officer                                      | 699    | 34.4              |
| Military occupation                          |        |                   |
| Combat-specific <sup>c</sup>                 | 1,511  | 94.9              |
| Armor/motor transport                        | 449    | 132.9             |
| Pilot/air crew                               | 126    | 30.1              |
| Repair/engineer                              | 3,292  | 97.0              |
| Communications/intelligence                  | 2,527  | 102.4             |
| Health care                                  | 1,000  | 99.6              |
| Other/unknown                                | 3,130  | 139.2             |

Abbreviation: No., number.

<sup>a</sup>Through Sept. 30, 2022.

<sup>b</sup>Incidence rate per 100,000 person-years.

<sup>c</sup>Infantry/artillery/combat engineering/armor.



**TABLE 2.** Crude and Adjusted Incidence Rate Ratios for Sunburn by Military Occupation Category

| Military occupation          | No.   | Crude rate | cIRR             | Adjusted rate | aIRR (95% CI)   |
|------------------------------|-------|------------|------------------|---------------|-----------------|
| Health care                  | 1,000 | 99.6       | 1.0 (0.1 - 16.8) | 46.1          | 1.5 (1.2 - 1.8) |
| Communications/intelligence  | 2,527 | 102.4      | 1.1 (0.1 - 17.3) | 41.3          | 1.3 (1.1 - 1.6) |
| Repair/engineer              | 3,292 | 97.0       | 1.0 (0.1 - 16.4) | 34.0          | 1.1 (0.9 - 1.3) |
| Pilot/air crew               | 126   | 30.1       | 0.3 (0.0 - 5.1)  | 14.9          | 0.5 (0.4 - 0.6) |
| Armor/motor transport        | 449   | 132.9      | 1.4 (0.1 - 22.4) | 48.5          | 1.5 (1.3 - 1.9) |
| Combat-specific <sup>a</sup> | 1,511 | 94.9       | --               | 31.5          | --              |
| Other/unknown (reference)    | 3,130 | 139.2      | 1.5 (0.1 - 23.5) | 40.8          | 1.3 (1.1 - 1.5) |

Abbreviations: No., number; cIRR, crude incidence rate ratio; aIRR, adjusted incidence rate ratio; CI, confidence interval.

<sup>a</sup> Infantry/artillery/combat engineering/armor.

the introduction of the ICD-10 code of “unspecified” may limit ascertainment of burn severity, potentially affecting accurate surveillance. A second limitation of this study is that the data could not differentiate sunburn during work hours versus non-work hours, challenging associations of occupation with sunburn risk.

Sunburn affects military readiness by removing service members from duty while their burns heal, affecting both garrison and combat missions. As a risk factor for future skin cancer, sunburn is a longitudinal concern for both the public health sector and the military due to the health care costs and time involved in management of melanoma and NMSC.<sup>11,12</sup> Emphasis on prevention should continue.

Sunburn is likely multifactorial, from limited access to sunscreen, to its lack of use, variable encouragement of use by peers or leadership, operational time constraints, and low prioritization or understanding of the long-term effects of sun damage.<sup>12,13</sup> Mitigation strategies can include pre-deployment or seasonal health promotion focused on increasing use of available sun-protective measures, including sunscreen, sunglasses, headgear, shade structures, and modified outdoor training times to early morning or later day/early evening.

Survey analysis of military-specific populations could help quantify incidence of sunburn that is more specific than clinical diagnoses, and could quantify occurrence of unreported sunburn. Survey research could evaluate behavioral practices, such as use of preventive measures, location and timing (on- or off-duty)

of sunburn, and inquiry about unreported burns, which may better inform sunburn-reduction strategies.

#### Author Affiliations

*Uniformed Services University of the Health Sciences, Bethesda, MD: LT Van Airsdale; Defense Health Agency, Armed Forces Health Surveillance Division: Dr. Stahlman, Ms. Hiban, CAPT Wells.*

#### Disclaimer

*The opinions and assertions expressed herein are those of the authors and do not reflect the official policy nor position of the Uniformed Services University of the Health Sciences or the Department of Defense.*

*LT Van Airsdale is a military service member. This work was prepared as part of official duties. Title 17, U.S.C., §105 provides that copyright protection under this title is not available for any work of the U.S. Government. Title 17, U.S.C., §101 defines a U.S. Government work as a work prepared by a military Service member or employee of the U.S. Government as part of that person's official duties.*

## References


1. Armed Forces Health Surveillance Branch. Sunburn among active component service members, U.S. Armed Forces, 2002–2013. *MSMR*. 2014;21(7):2-6.
2. Young AR and Tewari A. Sunburn. *UpToDate*. Updated Aug. 4, 2022. Accessed Oct. 10, 2023. <https://www.uptodate.com/contents/sunburn>
3. Guerra KC, Crane JS. Sunburn. In: *Stat-*

*Pearls*. StatPearls Publishing; 2023. Accessed Apr. 4, 2023. <https://www.ncbi.nlm.nih.gov/books/NBK534837>

4. Lee T, Taubman SB, Williams VF. Incident diagnoses of non-melanoma skin cancer, active component, U.S. Armed Forces, 2005-2014. *MSMR*. 2016;23(12):2-6.
5. Mabila S, Dreyer E. Surveillance snapshot: the top 10 incident cancers among active component service members, 2018-2022. *MSMR*. 2023;30(9):17.
6. U.S. Department of Defense. *Phase 1-a—Study on the Incidence of Cancer Diagnosis and Mortality Among Military Aviators and Aviation Support Personnel*. Jan. 2023.
7. Braun HA, Adler CH, Goodman M, Yeung H. Sunburn frequency and risk and protective factors: a cross-sectional survey. *Dermatol Online J*. 2021;27(4).
8. McKenzie C, Nahm WJ, Kearney CA, Zampella JG. Sun-protective behaviors and sunburn among US adults. *Arch Dermatol Res*. 2023;1-10. doi:10.1007/s00403-023-02547-z
9. Reuter NP, Bower M, Scoggins CR, Martin RC, McMasters KM, Chagpar AB. The lower incidence of melanoma in women may be related to increased preventative behaviors. *Am J Surg*. 2010;200(6):765-769. doi:10.1016/j.amjsurg.2010.06.007
10. National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services. Cancer Trends Progress Report/Sunburn. Updated Aug. 2023. Accessed Oct. 13, 2023. <https://progressreport.cancer.gov/prevention/sunburn>
11. Kao SYZ, Ekwueme DU, Holman DM, et al. Economic burden of skin cancer treatment in the USA: an analysis of the Medical Expenditure Panel Survey Data, 2012–2018. *Cancer Causes Control*. 2023;34:205-212. doi:10.1007/s10552-022-01644-0
12. Rosenberg A, Cho S. We can do better at protecting our service members from skin cancer. *Mil Med*. 2022;187:311-313. doi:10.1093/milmed/usac198
13. Powers JG, Patel NA, Powers EM, Mayer JE, Stricklin GP, Geller AC. Skin cancer risk factors and preventative behaviors among United States military veterans deployed to Iraq and Afghanistan. *J Invest Dermatol*. 2015;135(11):2871-2873. doi:10.1038/jid.2015.238

# Influenza Immunization Among U.S. Armed Forces Health Care Workers, August 2018–April 2023

**FIGURE.** Percentage of Health Care Specialists and Officers with Records of Influenza Vaccination, by Influenza Year (August 1–April 30) and Service, Active Component, U.S. Armed Forces, August 2018–April 2023



<sup>a</sup>Accurate immunization data for the Army 2020–2021 and 2022–2023 influenza seasons were not available via the Defense Medical Surveillance System (DMSS), which documented an under-estimation of influenza immunization rate for the Army, at 88.6% and 86.9%. Based on data from the Medical Protection System (MEDPROS), the overall influenza immunization rate among active component Army members was 94.4% for the 2020–2021 season and 93.8% for the 2022–2023 season.

The U.S. Advisory Committee on Immunization Practices recommends vaccination for all health care personnel against influenza to protect both themselves and their patients.<sup>1</sup> The Joint Commission's standard for infection control emphasizes that individuals infected with influenza virus are contagious to others before any signs or symptoms appear. The Joint Commission mandates 90% influenza vaccination for health care personnel, and health care organizations provide influenza vaccination programs for their practitioners and staff. Within the Department of Defense, seasonal influenza immunization is mandatory for all uniformed and health care personnel who provide direct patient care, and is recommended for all others (excluding those medically exempt).<sup>2–5</sup>

This Surveillance Snapshot covers a 5-year surveillance period (August 2018–April 2023) and presents the documented percentage of compliance for the influenza immunization requirement among active component health care personnel of the Army, Navy, and Air Force. In general, these health care personnel include health care specialists (DOD occupation code=13) and health care officers (DOD occupation code=26), but exclude veterinary medicine, environmental health, biomedical equipment maintenance and repair, and health services administration and logistics personnel. In the 2022–2023 influenza season, compliance rates ranged from 92.8% among Navy health care personnel to 93.8%<sup>b</sup> among Army health care personnel (Figure).

## REFERENCES

1. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention. Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2011;60(RR-7):1–45.
2. Headquarters, Departments of the Army, Navy, Air Force, and Coast Guard. Army Regulation 40-562, BUMEDINST 6230.15B, AFI 48-110\_IP, CG COMDTINST M6230.4G. Medical Services: Immunizations and Chemoprophylaxis for the Prevention of Infectious Diseases. Oct. 7, 2013.
3. Assistant Secretary of Defense (Health Affairs). Policy for Mandatory Seasonal Influenza Immunization for Civilian Health Care Personnel Who Provide Direct Patient Care in Department of Defense Military Treatment Facilities. Health Affairs Policy 08-005. Apr. 4, 2008.
4. Assistant Secretary of Defense (Health Affairs). Addition of Pandemic Influenza Vaccine or Novel Influenza Vaccine to the Policy for Mandatory Seasonal Influenza Immunization for Civilian Health Care Personnel Who Provide Direct Patient Care in Department of Defense Military Treatment Facilities. Health Affairs Policy 11-010. Jul. 28, 2011.
5. Defense Health Agency. Procedural Instruction 6025.34. Guidance for the DoD Influenza Vaccination Program (IVP). Aug. 21, 2020.

## The Role of Vaccines in Combatting the Potential “Tripledemic” of Influenza, COVID-19 and RSV

John K. Iskander, MD, MPH; Katie M. Martinez, PharmD; Nicole Hsu, MD, MPH

Common respiratory viruses are associated with substantial morbidity within the Military Health System (MHS). In 2022 more than 250,000 medical encounters were recorded within the MHS for respiratory illness among active component service members, with an additional 160,000 encounters for COVID-19.<sup>1</sup> Among non-service member beneficiaries, there were approximately 2 million encounters for respiratory infections in 2022, with just over one quarter of these among the pediatric 0-17 years age group.<sup>2</sup> During the most recent winter season in the Northern Hemisphere, the co-circulation at relatively high levels of influenza, SARS-CoV-2, and RSV was termed the “tripledeemic.”<sup>3</sup>

Persons at high risk, especially those over 65 years of age, can be hospitalized or die from complications of infection with influenza, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), respiratory syncytial virus (RSV), or from other frequently encountered pathogens. Mortality from respiratory viral illness also occurs among infants, children, and adolescents.<sup>4,5</sup>

With children returned to school, another respiratory infection season approaches. This year, however, health care providers have new tools to prevent these infections in their patients, in the form of newly licensed or updated vaccines and immunotherapeutics against RSV and SARS-CoV-2. Revised recommendations for annual influenza vaccines will potentially also allow more people to easily receive these products.<sup>6</sup>

Yearly influenza vaccination is recommended for almost all persons aged 6 months or older (including pregnant persons)<sup>6</sup> and is a requirement for both military personnel and all health care personnel working in military medical facilities.<sup>7</sup>

Data from the 2019-2020 influenza season show that influenza vaccination of U.S. Department of Defense (DOD) beneficiaries reduced influenza disease by 40-60%, and by 12-31% among military members; for methodological reasons, military vaccine effectiveness may be underestimated.<sup>8</sup>

The U.S. Centers for Disease Control and Prevention (CDC) states that the preferred time for vaccination for most persons who need only 1 dose of influenza vaccine is September or October. Vaccination should continue throughout the season, however, for as long as influenza viruses are circulating and vaccination is available. For children aged 6 months through 8 years, as well as pregnant persons in their third trimester, specific recommendations for timing of vaccination should be consulted.<sup>6</sup>

A notable change this year, which expands the population eligible for more ready vaccination, is the recommendation that all persons with egg allergy who are aged 6 months or older can receive influenza vaccine without special precautions. Regardless of the severity of prior egg reaction, egg allergy requires no additional safety measures for influenza vaccination. Observational data from numerous sources have documented the extreme rarity of anaphylactic-type allergic reactions to influenza vaccine in persons with egg allergy.<sup>6</sup> Consistent with best practice recommendations, all vaccines including influenza should be administered in settings where rapid recognition and treatment of acute hypersensitivity reactions can occur.<sup>9</sup>

Vaccines against SARS-CoV-2, the virus which causes COVID-19 disease and its sequelae, are in a transitional period. Bivalent formulations (which should no longer be used) have been replaced by monovalent formulations based on the

recent XBB.1.5 variant of the Omicron virus lineage.<sup>10</sup> Both protein and mRNA-based vaccines are available this fall.

The Food and Drug Administration (FDA) has approved monovalent vaccines for use as a single dose in all persons 5 years of age and older, provided that 2 months have elapsed following any prior COVID-19 vaccination. Infants and children 6 months through 4 years of age may receive 1, 2, or 3 doses of a monovalent vaccine, depending on COVID-19 vaccination history and which vaccine is used.<sup>10</sup> The CDC is recommending the newly available monovalent COVID-19 vaccines for everyone 6 months and older.

In explaining its recommendations, the CDC noted that while older and immunocompromised individuals are at highest risk for hospitalization and death due to COVID-19, serious outcomes continue among healthy children and adults.<sup>11,12</sup> Data indicate that, among those eligible for vaccination, individuals over age 75 and between 65-74 years of age have the highest hospitalization rates; continued vaccination of working-age adults (ages 18-49, the group that constitutes most military personnel) could prevent as many as 414 added hospitalizations over 6 months per 1 million doses administered.<sup>11</sup>

While it is well-documented that breakthrough infections can occur with COVID-19 vaccines, a recent evidence synthesis found that vaccination against Omicron variants was nearly 90% effective at preventing hospitalization due to COVID-19 within 6 weeks, with 71% effectiveness up to 16 weeks after vaccination.<sup>13</sup> The CDC has estimated that for every 1 million COVID-19 doses administered to adolescents over a period of 6 months, up to 95 hospitalizations, 19 ICU admissions, and 1 death can be prevented.<sup>11</sup> These estimates, complemented by a comprehensive

benefit and risk assessment of COVID-19 vaccination provided by the CDC, constitute reliable evidence supporting the CDC Advisory Committee on Immunization Practices (ACIP) recommendation.<sup>14</sup>

RSV, long known as a widespread and potentially serious pediatric pathogen, is also a known cause of serious illness in older adults.<sup>15</sup> The 2 new RSV vaccines, with recent FDA approval and CDC recommendation,<sup>16</sup> are a new addition to the armamentarium against respiratory viruses and their complications. Both vaccines use inactivated RSV proteins to stimulate active immune response.

In clinical trials, both vaccines showed high efficacy in preventing symptomatic lower respiratory infection with RSV. Two-season interim analyses showed 81.0% efficacy of the Pfizer vaccine against medically-attended lower respiratory tract disease, and 77.5% efficacy of the GSK vaccine against the same outcome.<sup>16</sup> The CDC ACIP recommends a single dose of either vaccine in persons aged 60 and over, using what it terms “shared clinical decision-making.”<sup>16</sup> This phrase generally describes health care provider discussion of vaccination options with their patients, taking into account their preferences, as well as medical fragility, advanced age, and other clinical characteristics that may increase risk of severe outcomes from RSV.<sup>17</sup> One of the newly-licensed RSV vaccines was also approved by the FDA for vaccination of pregnant persons for prevention of RSV infection in their infants, and the CDC has recently provided usage recommendations.<sup>18</sup>

Nirsevimab, a long-acting monoclonal antibody (mAb) designed to prevent severe RSV lower respiratory tract disease in infants and children under 20 months of age, was recently licensed by the FDA. ACIP recommends nirsevimab for all infants under 8 months of age either born during or entering their first RSV season, in addition to infants and children aged 8 to 19 months at increased risk of severe RSV disease who are entering their second RSV season.<sup>19</sup> Children at high risk include those with chronic lung disease requiring specific types of medical support, with severe immune compromise, or cystic fibrosis-meeting clinical criteria, in

addition to children of American Indian or Alaskan Native heritage.

An inherent limitation of nirsevimab is that as an antibody product rather than a true vaccine: It provides only passive immunity and does not result in longer-term immunologic memory. It is also not a treatment for RSV disease. Compared to palivizumab, a mAb previously approved by the FDA for RSV prevention in children up to 2 years of age,<sup>20</sup> nirsevimab has advantages of single dose administration, rather than requiring a 5-dose series, and is recommended for all infants entering RSV season instead of only certain high-risk pediatric patients. Maternal vaccination with the licensed and recommended RSV vaccine is an additional option for protection of all infants.<sup>18</sup>

While use of influenza, COVID-19, and RSV vaccine products are primary prevention measures against the “tripledemic,” the strategy has limitations. Only the influenza vaccine is currently required for military personnel. Only persons aged 60 years and older and children under 2 years of age can receive active and passive immunization against RSV, respectively. While preliminary laboratory evidence suggests that updated COVID-19 vaccines will offer cross-protection against recently-circulating SARS-CoV-2 Omicron virus variants such as BA.2.86,<sup>21</sup> it is unknown how clinically effective the newly updated formulations will be.

While shared vaccine decision-making for RSV protection is a patient-centered approach, it is also more time-consuming and may result in lower overall vaccine uptake. For example, the shared decision-making model precludes standing orders for RSV vaccination of eligible adults within the MHS.

Because none of this group of vaccines is expected to produce sterilizing immunity (i.e., absolute protection against infection), additional voluntary personal protection methods for preventing respiratory virus transmission are warranted. Recent DOD Force Health Protection Guidance includes recommendations for frequent use of hand hygiene and covering the mouth and nose when coughing or sneezing.<sup>22</sup> Health care providers should refrain from direct patient care while ill with respiratory

symptoms, and may wish to consider wearing a securely-fitting mask for the duration of the winter respiratory virus season. Enhancing ventilation in indoor settings, where feasible, may also limit respiratory virus spread. Treatment facilities can monitor local respiratory virus circulation conditions that could affect testing and mitigation strategies by consulting DOD resources from Armed Forces Health Surveillance Division, Global Emerging Infections Surveillance, and CDC sites including Fluview and the Covid Data Tracker.

Evidence-based methods for enhancing immunization (including standing orders where applicable and offers of vaccination at all visits) should be implemented. Patients should be screened for eligibility for all 3 vaccines during fall and winter season visits (**Table**). Consistent with CDC best practices, co-administration of recommended vaccines at the same visit is recommended.<sup>9</sup> Individuals who received the Southern Hemisphere influenza vaccine earlier this year should receive the Northern Hemisphere formulation this fall, as long as it has been 30 days since their most recent dose of influenza vaccine.

#### *Author affiliations*

*Immunization Healthcare Division, Public Health Directorate, Defense Health Agency, Falls Church, VA: CAPT Iskander, LTC Martinez, Lt Col Hsu.*

#### *Acknowledgements*

*Cecilia Mikita, MD, MPH, and Margaret Ryan, MD, MPH, Immunization Healthcare Division, Public Health Directorate, Defense Health Agency, Falls Church, VA.*

#### *Disclaimer*

*The views expressed in this document are those of the author(s) and do not necessarily reflect the official opinion, policy, nor position of the Defense Health Agency, the Department of Defense, or the U.S. Government. The mention of any non-federal entity or its products is for informational purposes only, and is not to be construed, implied, or interpreted, in any manner, as federal endorsement of that non-federal entity or its products.*



**TABLE.** Immunizations for Protection Against Selected Respiratory Viruses, 2023–2024

| Target Disease              | Required for Military Personnel | Recommended Age Group                  | Available Vaccine Products Within MHS                                                                                                                                                                                                     | Timing of Vaccination                                |
|-----------------------------|---------------------------------|----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|
| Influenza                   | Yes                             | ≥ 6 months                             | Fluzone Quadrivalent and High-Dose Quadrivalent (Sanofi Pasteur), <sup>a</sup> Afluria Quadrivalent, Flucelvax Quadrivalent, Fluad Quadrivalent (Seqirus), <sup>a</sup> Fluarix Quadrivalent and Flulaval Quadrivalent (GSK) <sup>a</sup> | September–October preferred                          |
| COVID-19                    | No                              | ≥ 6 months                             | Comirnaty (Pfizer), <sup>a</sup> Spikevax (Moderna), <sup>a</sup> Novavax <sup>a</sup> Monovalent                                                                                                                                         | ≥2 months after most recent dose of COVID-19 vaccine |
| RSV, adult <sup>b</sup>     | No                              | ≥ 60 years                             | Abrysvo preF (Pfizer), <sup>a</sup> Arexvy preF (GSK) <sup>a</sup>                                                                                                                                                                        | When vaccine is available locally                    |
| RSV, pediatric <sup>c</sup> | N/A                             | Pregnant persons                       | Abrysvo (Pfizer) <sup>a,c</sup>                                                                                                                                                                                                           | 32–36 weeks prenatally                               |
| RSV, pediatric <sup>c</sup> | N/A                             | 0–8 months<br>8–19 months <sup>d</sup> | Beyfortus mAb (Sanofi, Astra-Zeneca) <sup>a,c</sup>                                                                                                                                                                                       | Before start of RSV season <sup>e</sup>              |

Note: Per ACIP General Best Practice guidelines, all vaccines can be given with other vaccines.

Abbreviations: MHS, Military Health System; RSV, Respiratory Syncytial Virus; preF: Recombinant-stabilized prefusion F protein; mAb, Monoclonal antibody; ACIP, Advisory Committee on Immunization Practices.

<sup>a</sup> Product and company names are provided for identification only and do not imply endorsement.

<sup>b</sup> Recommended with shared clinical decision-making.

<sup>c</sup> Using shared clinical decision-making, either prenatal Abrysvo or Beyfortus is recommended for prevention among infants 0–8 months of age entering their first RSV season.

<sup>d</sup> Second dose only or specific high-risk infants entering their second RSV season.

<sup>e</sup> In most of the continental U.S., from October through end of March.

## References


1. Armed Forces Health Surveillance Division. Absolute and relative morbidity burdens attributable to various illnesses and injuries among active component members, U.S. Armed Forces, 2022. *MSMR*. 2023;30(6):3–11.
2. Armed Forces Health Surveillance Division. Update: absolute and relative morbidity burdens attributable to various illnesses and injuries among non-service member beneficiaries of the Military Health System, 2022. *MSMR*. 2023;30(7):11–20.
3. Patel TA, Jain B, Raifman J. Revamping public health systems: lessons learned from the “triple-demic.” *Am J Prev Med*. 2023:S0749-3797(23)00339-2.
4. Bixler D, Miller AD, Mattison CP, et al. SARS-CoV-2-associated deaths among persons aged <21 years—United States, February 12–July 31, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(37):1324–1329.
5. Shang M, Blanton L, Brammer L, Olsen SJ, Fry AM. Influenza-associated pediatric deaths in the United States, 2010–2016. *Pediatrics*. 2018;141(4):e20172918.
6. Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2023–24 influenza season. *MMWR Recomm Rep*. 2023;72(RR-2):1–25.
7. U.S. Department of Defense Immunization Program. U.S. Department of Defense Instruction 6205.02. Feb. 27, 2023.
8. Sayers DR, Iskander JK. Influenza vaccine effectiveness and test-negative study design within the Department of Defense. *Mil Med*. 2023;usac436.
9. Kroger A, Bahta L, Long S, Sanchez P. *General Best Practice Guidelines for Immunization*. Accessed Sep. 13, 2023. <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf>
10. U.S. Food and Drug Administration. Press Announcements. Sep. 11, 2023. Accessed Sep. 13, 2023. <https://www.fda.gov/news-events/press-announcements/fda-takes-action-updated-mrna-covid-19-vaccines-better-protect-against-currently-circulating>
11. Centers for Disease Control and Prevention. Respiratory Viruses. Sep. 12, 2023. Accessed Sep. 13, 2023. <https://www.cdc.gov/respiratory-viruses/whats-new/covid-vaccine-recommendations-9-12-2023.html>
12. Regan JJ, Moulia DL, Link-Gelles R, et al. Use of updated COVID-19 vaccines 2023–2024 formula for persons aged ≥6 months: recommendations of the Advisory Committee on Immunization Practices—United States, September 2023. *MMWR Morb Mortal Wkly Rep*. 2023;ePub.
13. Wu N, Joyal-Desmarais K, Ribeiro PAB, et al. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. *Lancet Respir Med*. 2023;11(5):439–452.
14. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices. Sep. 12, 2023. Accessed Oct. 18, 2023. <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-09-12/11-COVID-Wallace-508.pdf>
15. El Sherif M, Andrew MK, Ye L, et al. Leveraging influenza virus surveillance from 2012 to 2015 to characterize the burden of respiratory syncytial virus disease in Canadian adults ≥50 years of age hospitalized with acute respiratory illness. *Open Forum Infect Dis*. 2023;10(7):ofad315.
16. Melgar M, Britton A, Roper LE, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization Practices—United States, 2023. *MMWR Morb Mortal Wkly Rep*. 2023;72:793–801.
17. Havers FP, Whitaker M, Melgar M, et al. Characteristics and outcomes among adults aged ≥60 years hospitalized with laboratory-confirmed respiratory syncytial virus—RSV-NET, 12 states, July 2022–June 2023. *MMWR Morb Mortal Wkly Rep*. 2023;72:1075–1082.
18. Fleming-Dutra KE, Jones JM, Roper LE, et al. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus—associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices—United States, 2023. *MMWR Morb Mortal Wkly Rep*. 2023;ePub.
19. Jones JM, Fleming-Dutra KE, Prill MM, et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices—United States, 2023. *MMWR Morb Mortal Wkly Rep*. 2023;72:920–925.
20. Caserta MT, O’Leary ST, Munoz FM, Ralston SL, Committee on Infectious Diseases. Palivizumab prophylaxis in infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. *Pediatrics*. 2023;152(1):e2023061803.
21. Centers for Disease Control and Prevention. Respiratory Viruses. Sep. 15, 2023. Accessed Sep. 18, 2023. <https://www.cdc.gov/respiratory-viruses/whats-new/covid-19-variant-update-2023-09-15.html>
22. Memorandum for Senior Pentagon Leadership, Force Health Protection Guidance. Coronavirus Disease 2019 and Other Infectious Respiratory Diseases. Jul. 26, 2023.



# Reportable Medical Events at Military Health System Facilities Through Week 39, Ending September 30, 2023

Matthew W. R. Allman, MPH; Anthony R. Marquez, MPH; Katherine S. Kotas, MPH

## TOP 5 REPORTABLE MEDICAL EVENTS BY CALENDAR WEEK, ACTIVE COMPONENT (OCTOBER 1, 2022 - SEPTEMBER 30, 2023)



Note: There were 0 heat illness cases in week 51 of 2022 and week 4 of 2023. 0 cases of campylobacteriosis were reported in week 7 of 2023.

Abbreviation: No., number.

<sup>a</sup>Cases are shown on a log scale.

Reportable Medical Events (RMEs) are documented in the Disease Reporting System internet (DRSi) by health care providers and public health officials throughout the Military Health System (MHS) for monitoring, controlling, and preventing the occurrence and spread of diseases of public health interest or readiness importance. These reports are reviewed by each service's public health surveillance hub. The DRSi collects reports on over 70 different RMEs, including infectious and non-infectious conditions, outbreak reports, STI risk surveys, and tuberculosis contact investigation reports. A complete list of RMEs is available in the *2022 Armed Forces Reportable Medical Events Guidelines and Case Definitions*.<sup>1</sup> Data reported in these tables are considered provisional and do not represent conclusive evidence until case reports are fully validated.

Total active component cases reported per week are displayed for the top 5 RMEs for the previous year. Each month, the graph is updated with the 5 leading RMEs, and is presented with the current month's (September 2023) 5 leading RMEs, which may differ from previous months. COVID-19 is excluded from these graphs due to changes in reporting and case definition updates in 2023.

For questions about this report, please contact the Disease Epidemiology Branch at the Defense Centers for Public Health–Aberdeen. Email: [dha.apg.pub-health-a.mbx.disease-epidemiologyprogram13@health.mil](mailto:dha.apg.pub-health-a.mbx.disease-epidemiologyprogram13@health.mil).

### References

1. Armed Forces Health Surveillance Division. Armed Forces Reportable Medical Events. Accessed Sep. 6, 2023. <https://health.mil/Reference-Center/Publications/2022/11/01/Armed-Forces-Reportable-Medical-Events-Guidelines>
2. Defense Manpower Data Center. Department of Defense Active Duty Military Personnel by Rank/Grade of Service, October 31, 2022. <https://dwp.dmdc.osd.mil/dwp/app/dod-data-reports/workforce-reports>
3. Defense Manpower Data Center. Armed Forces Strength Figures for January 31, 2023. <https://dwp.dmdc.osd.mil/dwp/app/dod-data-reports/workforce-reports>
4. Navy Medicine. Surveillance and Reporting Tools–DRSi: Disease Reporting System Internet. <https://www.med.navy.mil/Navy-Marine-Corps-Public-Health-Center/Preventive-Medicine/Program-and-Policy-Support/Disease-Surveillance/DRSi>

**TABLE.** Reportable Medical Events, Military Health System Facilities, Week Ending September 30, 2023 (Week 39)<sup>a</sup>

| Reportable Medical Event <sup>b</sup>                      | Active component <sup>c</sup> |           |          |          |             | MHS beneficiaries <sup>d</sup> |
|------------------------------------------------------------|-------------------------------|-----------|----------|----------|-------------|--------------------------------|
|                                                            | August                        | September | YTD 2023 | YTD 2022 | Total, 2022 | September                      |
|                                                            | no.                           | no.       | no.      | no.      | no.         | no.                            |
| Amebiasis                                                  | 1                             | 0         | 12       | 7        | 13          | 0                              |
| Arboviral diseases, neuroinvasive and non-neuroinvasive    | 2                             | 0         | 2        | 1        | 1           | 1                              |
| Brucellosis                                                | 0                             | 0         | 0        | 2        | 2           | 0                              |
| COVID-19-associated hospitalization and death <sup>e</sup> | 1                             | 8         | 82       | 0        | 7           | 69                             |
| Campylobacteriosis                                         | 41                            | 18        | 217      | 183      | 230         | 13                             |
| Chikungunya virus disease                                  | 1                             | 0         | 1        | 1        | 1           | 0                              |
| Chlamydia trachomatis                                      | 1,650                         | 1,417     | 13,231   | 15,320   | 19,432      | 182                            |
| Cholera                                                    | 0                             | 0         | 4        | 1        | 2           | 0                              |
| Coccidioidomycosis                                         | 3                             | 1         | 19       | 11       | 15          | 2                              |
| Cold weather injuries <sup>f</sup>                         | 3                             | 1         | 102      | 113      | 151         | 0                              |
| Cryptosporidiosis                                          | 5                             | 6         | 59       | 35       | 46          | 7                              |
| Cyclosporiasis                                             | 0                             | 0         | 15       | 9        | 10          | 1                              |
| Dengue virus infection                                     | 2                             | 2         | 6        | 1        | 1           | 1                              |
| <i>E. coli</i> , Shiga toxin-producing                     | 7                             | 13        | 60       | 59       | 67          | 4                              |
| Ehrlichiosis/anaplasmosis                                  | 1                             | 0         | 29       | 3        | 3           | 0                              |
| Giardiasis                                                 | 7                             | 7         | 59       | 55       | 71          | 5                              |
| Gonorrhea                                                  | 252                           | 222       | 2,068    | 2,634    | 3,305       | 23                             |
| <i>Haemophilus influenzae</i> , invasive                   | 0                             | 0         | 1        | 1        | 1           | 1                              |
| Hantavirus disease                                         | 0                             | 0         | 1        | 0        | 1           | 0                              |
| Heat illness <sup>f</sup>                                  | 364                           | 113       | 1,178    | 1,149    | 1,213       | 1                              |
| Hepatitis A                                                | 0                             | 1         | 7        | 11       | 16          | 1                              |
| Hepatitis B                                                | 10                            | 14        | 116      | 94       | 119         | 11                             |
| Hepatitis C                                                | 5                             | 3         | 41       | 47       | 57          | 8                              |
| Influenza-associated hospitalization <sup>g</sup>          | 1                             | 1         | 7        | 118      | 148         | 1                              |
| Lead poisoning, pediatric <sup>h</sup>                     | 0                             | 0         | 0        | 0        | 0           | 5                              |
| Legionellosis                                              | 0                             | 0         | 3        | 2        | 4           | 2                              |
| Leishmaniasis                                              | 0                             | 0         | 1        | 1        | 1           | 0                              |
| Leprosy                                                    | 2                             | 0         | 2        | 1        | 1           | 0                              |
| Leptospirosis                                              | 1                             | 0         | 3        | 1        | 1           | 0                              |
| Lyme disease                                               | 5                             | 6         | 56       | 54       | 65          | 8                              |
| Malaria                                                    | 2                             | 4         | 19       | 22       | 26          | 0                              |
| Meningococcal disease                                      | 0                             | 0         | 2        | 1        | 2           | 0                              |
| Mpox                                                       | 0                             | 0         | 0        | 87       | 93          | 0                              |
| Norovirus                                                  | 17                            | 14        | 346      | 182      | 221         | 26                             |
| Pertussis                                                  | 0                             | 0         | 4        | 8        | 10          | 1                              |
| Post-Exposure prophylaxis against rabies                   | 46                            | 47        | 446      | 399      | 514         | 26                             |
| Q fever                                                    | 0                             | 0         | 2        | 3        | 3           | 0                              |
| Rubella                                                    | 0                             | 0         | 2        | 2        | 3           | 0                              |
| Salmonellosis                                              | 12                            | 17        | 81       | 104      | 122         | 20                             |
| Schistosomiasis                                            | 0                             | 0         | 0        | 1        | 1           | 0                              |
| Severe acute respiratory syndrome (SARS)                   | 0                             | 0         | 0        | 1        | 1           | 0                              |
| Shigellosis                                                | 10                            | 8         | 56       | 26       | 33          | 1                              |
| Spotted fever rickettsiosis                                | 4                             | 1         | 30       | 56       | 70          | 0                              |
| Syphilis (all)                                             | 78                            | 70        | 686      | 787      | 1,048       | 11                             |
| Toxic shock syndrome                                       | 0                             | 0         | 1        | 0        | 0           | 0                              |
| Trypanosomiasis                                            | 0                             | 0         | 1        | 1        | 1           | 0                              |
| Tuberculosis                                               | 2                             | 1         | 7        | 7        | 11          | 0                              |
| Tularemia                                                  | 0                             | 0         | 1        | 0        | 0           | 0                              |
| Typhoid fever                                              | 0                             | 1         | 2        | 0        | 0           | 0                              |
| Typhus fever                                               | 0                             | 0         | 2        | 1        | 1           | 0                              |
| Varicella                                                  | 0                             | 1         | 9        | 12       | 16          | 5                              |
| Total case counts                                          | 2,535                         | 1,997     | 19,079   | 21,614   | 27,160      | 436                            |

Abbreviations: RME, reportable medical event; MHS, Military Health System; YTD, year to date; no., number.

<sup>a</sup>RMEs reported through the DRSi as of October 31, 2023 are included in this report. RMEs were classified by date of diagnosis, or where unavailable, date of onset. Monthly comparisons are displayed for the periods August 1, 2023–August 31, 2023 and September 1, 2023–September 30, 2023. Year-to-date comparison is displayed for the period January 1, 2023–September 30, 2023 for MHS facilities. Previous year counts are provided as the following: previous year YTD—January 1, 2022–September 30, 2022; total 2022—January 1, 2022–December 31, 2022.

<sup>b</sup>RME categories with 0 reported cases among active component service members and MHS beneficiaries for the time periods covered were not included in this report.

<sup>c</sup>Services included in this report include Army, Navy, Air Force, Marine Corps, Coast Guard, and Space Force, including personnel classified as FMP 20 with duty status of AD, Recruit, or Cadet in DRSi.

<sup>d</sup>Beneficiaries included the following: individuals classified as FMP 20 with duty status of Retired and individuals with all other FMPs except 98 and 99. Civilians, contractors, and foreign nationals were excluded from these counts.

<sup>e</sup>Only cases reported after May 4, 2023 case definition update; includes only cases resulting in hospitalization or death; does not include cases of hospitalization/death reported under previous COVID-19 case definition.

<sup>f</sup>Only reportable for active component service members.

<sup>g</sup>Influenza-associated hospitalization is reportable only for individuals aged 65 years or younger.

<sup>h</sup>Pediatric lead poisoning is reportable only for children aged 6 years or younger.



***Medical Surveillance Monthly Report (MSMR)***, in continuous publication since 1995, is produced by the Armed Forces Health Surveillance Division (AFHSD) of the Defense Health Agency (DHA) Public Health Directorate. AFHSD is a designated public health authority within the Defense Health Agency. The *MSMR* provides evidence-based estimates of the incidence, distribution, impact, and trends of illness and injuries among U.S. military members and associated populations. Most reports in the *MSMR* are based on summaries of medical administrative data that are routinely provided to the AFHSD and integrated into the Defense Medical Surveillance System for health surveillance purposes.

- *Archive*: Past issues of the *MSMR* are available as downloadable PDF files at [www.health.mil/MSMRArchives](http://www.health.mil/MSMRArchives).
- *Online Subscriptions*: Submit subscription requests at [www.health.mil/MSMRSubscribe](http://www.health.mil/MSMRSubscribe).
- *Editorial Inquiries*: Call (301) 319-3240 or email [dha.ncr.health-surv.mbx.msmr@health.mil](mailto:dha.ncr.health-surv.mbx.msmr@health.mil).
- *Instructions for Authors*: Information about article submissions is provided at [www.health.mil/MSMRInstructions](http://www.health.mil/MSMRInstructions).

All material in the *MSMR* is in the public domain and may be used and reprinted without permission. Citation formats are available at [www.health.mil/MSMR](http://www.health.mil/MSMR).

Opinions and assertions expressed in the *MSMR* should not be construed as reflecting official views, policies, or positions of the Department of Defense or the United States Government. The use of the name of any specific manufacturer, commercial product, commodity, or service in this publication does not imply endorsement by the Armed Forces Health Surveillance Division, the Defense Health Agency, or the Department of Defense.

#### **Interim Editor-in-Chief**

Angelia A. Eick-Cost, PhD

#### **Contributing Editors**

Kristen R. Rossi, MPH

Andrew R. Wiesen, MD, MPH

#### **Writer/Editor**

Bulbulgul Aumakhan, PhD

#### **Managing/Production Editor**

Robert Pursley

#### **Editor Emeritus**

John F. Brundage, MD, MPH

#### **Layout/Design**

Darrell Olson

#### **Data Analysts**

Prabhavi Denagamage, MPH

Erika Dreyer, MPH

#### **Director, Defense Health Agency Public Health**

RDML Brandon L. Taylor, PharmD, BCPS (USPHS)

#### **Chief, Armed Forces Health Surveillance Division**

Col Patrick W. Kennedy, MA, MS (USAF)

#### **Editorial Oversight**

CAPT Richard S. Langton, MD, MPH (USN)

Mark V. Rubertone, MD, MPH

Follow us:



Facebook: <https://www.facebook.com/AFHSDPAGE/>



Twitter: <https://twitter.com/AFHSDPAGE>

ISSN 2158-0111 (print)

ISSN 2152-8217 (online)

#### ***Medical Surveillance Monthly Report (MSMR)***

Armed Forces Health Surveillance Division

11800 Tech Road, Suite 220

Silver Spring, MD 20904

